This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Public health messages have told us for decades that if you smoke, you should quit. And if you don’t smoke, don’t start. But a new study suggests smoking may be even worse than we thought. The study , published Wednesday in Nature, underscores the importance of never lighting up that first cigarette, based on its conclusion that smoking has much longer harmful effects on immune responses than previously understood.
The Federal Trade Commission is launching a probe into the extent to which group purchasing organizations and wholesalers may contribute to ongoing shortages of key medicines at hospitals and other facilities across the country. The agency will explore how these companies — which are responsible for brokering and distributing countless medicines — might misuse their market power to influence pricing and availability.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
If you have high blood pressure, it’s increasingly likely that your doctor or your insurer will offer you a blood pressure cuff or an educational app to help you get it under control. While potentially impactful, these tools may not be reaching marginalized people who don’t regularly have access to good health care — and who may benefit the most from the tools.
The pharma giant’s leader of a collective devoted to health equity discusses how companies can put their money where their mouth is to reach communities in need.
It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira , used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders.
It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira , used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders.
Discover how artificial intelligence (AI) is revolutionising the drug development process and transforming the way FDA-approved drugs are produced, ensuring compliance and optimising the supply chain. Learn more about the future of AI in pharmaceuticals.
A leaked version of a proposed agreement between India and the European Free Trade Association is causing alarm among civil society and patient advocacy groups over concerns the deal would delay access to affordable generic versions of newer, lifesavings medicines for several years. The language in a draft agreement, which is expected to be concluded by April, suggests changes would have to be made to India’s patent and regulatory laws.
The General Pharmaceutical Council (GPhC) has announced the appointment of five new members to its governing council, including a community pharmacist. Adeyemi (Ade) Williams, superintendent pharmacist and director of M J Williams Pharmacy, and lead pharmacist at the Bedminster Pharmacy, Bristol, will begin his term on 1 April 2024. Joining him will be Professor Dianne […] The post GPhC announces five new council members appeared first on The Pharmacist.
After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals. The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The company and partner Biogen say signs from payers and doctors suggest the launch of Zurzuvae, the first oral therapy for PPD, is off to a good start.
Last week, the Washington Post published an op-ed by former CDC Director Tom Frieden titled, “It’s the world’s leading killer. Make it the focus of the next breakthrough.” Frieden writes, “Hypertension, the ‘silent killer,’ is the deadliest but most neglected and widespread pandemic of our time, killing more than 10 million people a year worldwide.
Latigo Biotherapeutics has raised $135 million to develop drugs that block NaV1.8, a target shared by a Vertex therapy that just succeeded in Phase 3 testing.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! And it’s Meghana again. Today, we discuss how Biogen’s missed the mark with Leqembi, but how it’s also not exactly a surprise. We see a new startup emerge that aims to compete with Vertex Pharmaceuticals, and learn of Phase 1 results for Replicate’s srRNA rabies vaccine.
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.
Ipsen has won FDA approval for first-line use of its pancreatic cancer therapy Onivyde, saying it is now part of a potential new “standard-of-care” for patients
WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts. Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection.
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
Gilead Sciences has agreed to acquire CymaBay Therapeutics for a total equity value of $4.3 billion. Gilead confirmed that CymaBay’s lead product candidate seladelpar has a best-in-disease profile for second-line primary biliary cholangitis (PBC). This is based on data from the Phase III RESPONSE trial. The company shared that seladelpar is an oral, selective peroxisomeproliferator-activated receptor delta (PPARδ) agonist.
Years of wrangling have ended in stalemate as campaigners question fairness of system for low and middle-income countries The World Trade Organization has failed to reach an agreement to waive intellectual property rights on Covid-19 tests and treatments for poorer countries. Members of the Trade-Related Aspects of Intellectual Property Rights (Trips) council said it could not reach consensus after years of discussion, despite the “considerable efforts” of members.
The development of drug products containing live anaerobic bacterial strains as the active pharmaceutical ingredient and where potency and shelf-life is typically associated with viable cell quantification, poses unique challenges when compared to both small and large molecule development therapeutics. It is the uniqueness of the strain and perceived inter-cellular variations (sub-populations) resulting from high viable cell densities during growth (fermentation) and the subsequent harvest and d
Stella Vnook, a seasoned veteran in the pharmaceutical industry with extensive experience in senior leadership roles at Catalent, Merck, and Diverse Biotech, has been a prominent figure in the field, particularly in oncology, for over 25 years.
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
A report by Allied Market Research predicts that the global pharmaceutical suspension market will reach $83.8 billion by 2032. Having valued $55.5 billion in 2022, the research expected that the market will reach a CAGR of 4.2 percent between 2023 and 2032. Factors driving the global pharmaceutical suspension market One of the main factors anticipated to propel the growth of the pharmaceutical suspension market is the availability of generic pharmaceutical suspensions, the research asserted.
A drug used to treat rheumatoid arthritis could also prevent the disease in individuals deemed to be at risk. Results from a Phase 2b clinical trial, published in The Lancet by researchers led by King's College London, provides hope for arthritis sufferers after it was shown that the biologic drug abatacept reduces progression to this agonising chronic inflammatory disease.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
It's Valentine’s Day—and commercial plan sponsors remain smitten with copay accumulators and maximizers. Our latest update finds that as of late 2023, about half of commercial lives were in plans that utilize a copay accumulator and/or a maximizer. These programs’ growth continues to divert the value of a manufacturer’s copay support payments away from patients and toward plans and PBMs.
The biotech is planning to dissolve less than four years after launching with plans to license drugs and market them in China and other Asian countries.
Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Onivyde (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (Nalirifox) as a first line treatment for adult patients with metastatic pancreatic adenocarcinoma (mPDAC). This approval is the second for an Onivyde regimen in mPDAC, following […] The post FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma treatment appeared first on
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content